002788 鹭燕医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.0348.68411.31712.83013.243
总资产报酬率 ROA (%)0.5082.1582.8293.0843.170
投入资产回报率 ROIC (%)0.6492.7853.6654.0514.154

边际利润分析
销售毛利率 (%)6.7127.0767.4477.6047.785
营业利润率 (%)1.6891.7832.2382.3612.394
息税前利润/营业总收入 (%)2.4712.6373.2483.4893.525
净利润/营业总收入 (%)1.2341.3131.6991.8371.803

收益指标分析
经营活动净收益/利润总额(%)106.303108.761103.627103.549110.971
价值变动净收益/利润总额(%)-10.681-3.810-4.132-2.590-1.485
营业外收支净额/利润总额(%)-0.178-0.704-1.0640.1840.014

偿债能力分析
流动比率 (X)1.1071.0911.1471.1611.174
速动比率 (X)0.8040.7750.8140.8400.867
资产负债率 (%)74.59275.18674.74574.75876.318
带息债务/全部投入资本 (%)66.70766.42465.91164.99067.054
股东权益/带息债务 (%)47.68948.18748.74650.25745.453
股东权益/负债合计 (%)33.91032.83533.47533.41730.254
利息保障倍数 (X)3.1463.0433.1423.1063.118

营运能力分析
应收账款周转天数 (天)108.295103.906101.460104.071100.805
存货周转天数 (天)53.06253.78951.67250.28748.377